ABSTRACT
Os autores relatam caso clinico de paciente com esquistossomose mansonica, tratado com oxamniquine oral em dose unica de 15mg/Kg, que apresenta como efeito colateral um bloqueio atrio-ventricular incompleto tipo Mobitz I, com parada sinusal e escape ventricular. Concluem que, apesar de a oxamniquine ser eficaz e segura, pode ser determinante de cardiotoxicidade.
Subject(s)
Humans , Male , Adolescent , Arrhythmias, Cardiac/etiology , Oxamniquine/therapeutic use , Schistosomiasis mansoni/therapy , Oxamniquine/adverse effectsSubject(s)
Humans , Male , Child , Oxamniquine/adverse effects , Schistosomiasis mansoni , Lung Diseases , Pulmonary Heart Disease , BrazilABSTRACT
By means of electrophoresis quantitative estimation of serum protein components were made at various intervals before and after treatment with oxamniquine. During infection of mice with S. mansoni serum protein fractions showed marked alterations. Significant increase of total protein, alpha-2 globulin and beta globulin started at week 4 and alpha-1 globulin and gamma globulin at week 6. The significant decrease of globulins at week 6 resulted in reduced albumin globulin ratios. Some of these changes developed during maturation of worms and became more evident with initiation of egg deposition. The possible cause of these variations and their significance was discussed. Oxamniquine treatment of the drug to normal was followed by temporary increase of serum albumin
Subject(s)
Oxamniquine/adverse effects , Blood ProteinsABSTRACT
Foram tratados com oxamniquine (dose oral única de 12,5 a 15 mg e 15 a 20 mg/kg de peso, para maiores e menores de 15 anos respectivamente) 180 indivíduos com esquistossomose mansoni, matriculados na Clínica de Doenças Infecciosas e Parasitárias do Hospital das Clínicas da Faculdade de Medicina da Universidade de Säo Paulo. As idades variam de 5 a 65 anos e as formas clínico-evolutivas prevalentes foram a intestinal e hepatointestinal. Os principais efeitos colaterais neuropsiquiátricos foram:sonolência (50,6%), tontura (41,1%), cefaléia (16,1%), amnésia transitória (2,2%), alteraçöes de comportamento (1,7%), tremores (1,1%) e convulsäo (1,1%). Em 20 indivíduos foi avaliada a neurotoxicidade da froga através de eletroencefalografia, antes e após o tratamento. Em 3 (15%), foram detectados alteraçöes no traçado, sem contudo apresentarem manifestaçöes clínicas neuropsiquiátricas. Os resultados demonstraram ser o oxamniquine determinante de efeitos tóxico-colaterais na esfera neuropsiquiátrica
Subject(s)
Child, Preschool , Child , Adolescent , Adult , Middle Aged , Humans , Male , Female , Central Nervous System/drug effects , Oxamniquine/adverse effects , Schistosomiasis/drug therapy , Electroencephalography , Oxamniquine/therapeutic use , Schistosoma mansoni/drug effectsABSTRACT
Trinta e cinco pacientes com salmonelose septicêmica prolongada (SSP) foram selecionados para o estudo. Vinte (Grupo 1), foram tratados com a oxamniquine oral (15-20mg/Kg de peso, dose única) e 15 (Grupo 2) com o cloranfenicol (50mg%Kg de peso/15-20 dias). Realizaram-se exames clínico, laboratorial e radiológico antes e após o tratamento. Oito pacientes do Grupo 1 (40%) exibiram uma ou mais queixas após o tratamento. Exceçäo feita a um paciente que apresentou crise convulsiva, uma hora após a ingestäo do medicamento, os demais efeitos colaterais foram de pouco importância. Näo se observou efeito tóxico da oxamniquine à luz dos exames complementares realizados após o tratamento. Os pacientes do Grupo 2, näo apresentaram qualquer manifestaçäo que pudesse ser imputada ao cloranfenicol. No Grupo 1, 90% dos pacientes foram considerados curados e no Grupo 2, 93% também o foram. Os Autores concluem pela boa eficácia e baixa toxicidade da oxamniquine no tratamento da SSP
Subject(s)
Child, Preschool , Child , Adolescent , Adult , Humans , Male , Female , Chloramphenicol/therapeutic use , Oxamniquine/therapeutic use , Salmonella Infections/drug therapy , Sepsis/drug therapy , Clinical Trials as Topic , Oxamniquine/adverse effectsABSTRACT
The material of this work comprised 25 cases with active intestinal bilharziasis associating bilharzial hepatosplenomegaly with and without cor-pulmonale. All patients were given pxamniquine with a total dose of 60 mg/kgm body weight twice daily for three successive days. All patients were subjected to Biochemical and haematological studies as well as E.C.G. and echocardiography before, one week and one month after oxamniquine. Compacatative electrocardiography though revealing nonsignificant changes as regards the E.C.G. parameters as minor incidence% of S-T and T wave changes and arrhythmia one week after oxamniquine therapy, corrective reversbility in these parameters was the rule. Echocardiographic assessement for left ventricular performance and for indices of myocardial contractility revealed non significant changes short of denoting left vnetricular dysfunction one week after oxamniquine and moreover reversibility pattern for these changes was evident one month after therapy. A non-significant increase in the pulmonary arterial pressure was observed one week after therapy to diminish one month later on. Non-significant aberrations in liver and renal functions as well as non significant increase in HB, R.B.C.S. and W.B.O.S. were observed one week after therapy together with corrective reversibility for these aberration were demonstrable one month later. Cure rate after oxamniquine therapy was 80% in group of hepatosplenomegaly and in the group of compensated bilharzial cor-pulmonale and 60% in decompensated group of bilharzial cor-pulmonale. A suggestion for further work can be targeted towards a comparative evaluation for efficacy and safety of this drug in therapy of active bilharziasis in compensated and decompensated cardiac patients with cardiac disorders aetiologically non-related to bilharzial infection